GHRP-2 (Pralmorelin): What It Is and How It Works

At a glance

What is GHRP-2?

GHRP-2, with the generic name pralmorelin, is a synthetic six-amino acid peptide that imitates ghrelin to stimulate growth hormone release. It is sold through wellness and "research peptide" channels and promoted for muscle gain, recovery, and increased appetite. Unlike most unapproved peptides, it has a narrow legitimate role: it is approved in Japan as a diagnostic agent to test the pituitary's growth hormone capacity.

How does it work?

GHRP-2 activates the growth hormone secretagogue receptor (the ghrelin receptor) on the pituitary. Activating it has three reported effects:

• It triggers a pulse of growth hormone, and growth hormone pulses raise IGF-1 downstream.
• It tends to modestly raise other hormones such as cortisol and prolactin.
• Like other ghrelin mimics, it can stimulate appetite.

The marketed muscle and recovery claims are extrapolated from this hormone effect rather than demonstrated. This describes the proposed mechanism, separate from proven outcomes.

Is it FDA-approved?

No. GHRP-2 is not approved by the FDA; its only regulatory approval is as a diagnostic agent in Japan. The table below sets out its status with each regulator.

What does the research show?

The validated human data concern diagnosis, not treatment. According to PubMed, GHRP-2 is used to probe pituitary growth hormone reserve, as in a study of the growth hormone response, which is a diagnostic application rather than a wellness-outcome trial. There are no controlled human trials showing that GHRP-2 improves muscle, fat, recovery, or aging. The marketed uses rest on its ability to raise growth hormone, not on demonstrated benefit.

Evidence strength

Low research: It is validated only as a short-acting growth hormone diagnostic stimulus, with no controlled human evidence supporting the marketed muscle, recovery, or anti-aging uses.

Sources: a study of GHRP-2 and the growth hormone response (Teramoto et al., Growth Hormone & IGF Research, 2023, DOI: 10.1016/j.ghir.2023.101545), indexed on PubMed; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.